Publication

Performance of idarucizumab as antidote of dabigatran in daily clinical practice

van der Wall, S. J., van Rein, N., van den Bemt, B., Kruip, M. J. H. A., Meijer, K., te Boome, L. C. J., Simmers, T. A., Alings, A. M., Tieleman, R., Westerweel, P. E., Klok, F. & Huisman, M., Mar-2019, In : Europace. 21, 3, p. 414-420 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Performance of idarucizumab as antidote of dabigatran in daily clinical practice

    Final publisher's version, 238 KB, PDF document

    Request copy

DOI

  • Sake J. van der Wall
  • Nienke van Rein
  • Bart van den Bemt
  • Marieke J. H. A. Kruip
  • Karina Meijer
  • Liane C. J. te Boome
  • Tim A. Simmers
  • A. MarcoW. Alings
  • Robert Tieleman
  • Peter E. Westerweel
  • FrederikusA. Klok
  • MennoV. Huisman

Aims Because practice-based data on the usage of idarucizumab for urgent dabigatran reversal is unavailable, we evaluated the appropriateness of idarucizumab usage, its haemostatic effectiveness and clinical outcomes.

Methods and results An observational cohort study was performed including consecutive patients who were treated with idarucizumab between 2016 and 2018. Appropriate usage was assessed with predefined criteria. Post-reversal effectiveness was evaluated according to International Society on Thrombosis and Haemostasis (ISTH) recommendations. Patients were followed for 90 days for occurrence of thromboembolism, (re-) bleeding and death. Idarucizumab was used in 88 patients, of whom 53 (60%) presented with severe bleeding (20 gastrointestinal and 18 intracranial) and 35 (40%) requiring urgent surgical intervention. Use of idarucizumab was judged inappropriate in 25 patients (28%). Effective haemostasis was achieved in 32 of 48 (67%) bleeding patients in whom assessment was possible. Seven of 16 patients with major bleeding who did not achieve effective haemostasis (five intracranial) died, compared with two of 32 patients with effective haemostasis (relative risk 7.0, 95% confidence interval 1.6-30). Four patients (4.2%) developed thromboembolism [2 (2.1%) within 30 days] and four patients (4.2%) re-bleeding, all within 10 days. Seventeen patients (19%) died; 10 (11%) within 5 days.

Conclusion In this practice-based cohort, idarucizumab use was considered inappropriate in 28% of patients. Effective haemostasis was achieved in two-third of bleeding patients and was associated with lower mortality risk. Clinical outcomes were similar to those observed in the RE-VERSE AD trial, comprising re-bleeds and thromboembolism, and a high-mortality rate.

Original languageEnglish
Pages (from-to)414-420
Number of pages7
JournalEuropace
Volume21
Issue number3
Publication statusPublished - Mar-2019

    Keywords

  • Idarucizumab, Dabigatran, Bleeding, Reversal, PROTHROMBIN COMPLEX CONCENTRATE, VITAMIN-K ANTAGONISTS, ORAL ANTICOAGULANTS, MANAGEMENT, REVERSAL, HEMORRHAGE, SAFETY, STROKE, CARE, SSC

View graph of relations

ID: 92375198